RNA sequencing enables neoantigen discovery and vaccine validation in breast and lung cancer
RNA sequencing alone enables efficient neoantigen prediction and vaccine design, and the neoantigen vaccine can elicit an antitumor reaction against mouse breast cancer and lung cancer. The study showed that neoantigen prediction using RNA sequencing alone holds promise as a novel immunotherapeutic approach for cancer patients.
Authors
- Jilin Wang (ORCID: https://orcid.org/0000-0001-8385-253X)
- Da-peng Mo
- Yicheng Xiong (ORCID: https://orcid.org/0009-0006-0775-6670)
- Guan Wang (ORCID: https://orcid.org/0000-0003-2341-3054)
- Xiaoping Su (ORCID: https://orcid.org/0000-0003-1824-943X)
- Xiaohua Zhang (ORCID: https://orcid.org/0000-0003-1981-0225)
- Mingdong Lu (ORCID: https://orcid.org/0000-0002-9703-5458)
- Lu Chen (ORCID: https://orcid.org/0000-0002-6208-1438)
- Weihong Sun (ORCID: https://orcid.org/0000-0002-2422-7440)
- Hongye Hu (ORCID: https://orcid.org/0000-0002-0941-6892)
- Danhong Lu
- Guanli Huang (ORCID: https://orcid.org/0000-0003-2257-5078)
Institutions
- Qingdao University (CN)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Municipal Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1682312
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00